EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast.

摘要: Most breast cancers are invasive ductal carcinomas (IDC), and the prognosis for patients with IDC is affected by size histological grade of tumor, presence or absence expression estrogen receptor (ER) progesterone (PR), overexpression human epidermal growth factor 2 (HER-2) protein, lymph node metastasis, vascular perineural invasion. Currently, classified according to immunoexpression ER, PR, HER-2.1 Among triple-negative (ER-, PR-, HER-2-) (TNBC), basal-like cancer (BLBC) group that expresses 1 (EGFR) and/or cytokeratin (CK) 5/6 associated distinctive features, high grade, worse overall disease-free survival compared hormone receptor-positive HER-2-overexpressing groups.2 EGFR an important biomarker diagnosis BLBC, its has been reported in 5-36% Asian cancers, as determined immunohistochemistry; inversely correlated ER expression.3,4 Overexpression EGFR TNBC confers improved response neo-adjuvant treatment; however, co-expression HER-2 enhanced tumorigenesis increased metastatic potential cell lines.5,6 EGFR a member family tyrosine kinase proteins molecular target variety including colorectal cancer, non-small lung (NSCLC), squamous carcinoma head neck.7,8 Tyrosine inhibitors monoclonal antibodies have evaluated mutations corresponding gene, EGFR, increase copy numbers.9,10 However, gene amplification occurs low frequency, activating extremely rare cancers.4,11-15 Thus, date, EGFR-targeted therapy yielded disappointing results. In this study, was studied changes number IDC. The clinicopathological features were among co-expressing tumors, those tumors co-expressed CK5/6, EGFR-expressing lacked CK5/6 expression.